Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Patent
1997-05-21
2000-02-01
Kemmerer, Elizabeth
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
435212, 435219, 604403, C12N 964
Patent
active
060201819
ABSTRACT:
The invention provides a method of causing the degradation of fibrin(ogen) (i.e., fibrin, fibrinogen, and related substances) by means of a fibrinolytic matrix metalloproteinase, preferably an MMP-3 or MMP-7. The method of the invention can be performed in vitro to provide diagnostic information characterizing fibrin(ogen) and fibrinolytic physiology. The method can also be performed in vivo as a method of thrombolytic therapy in which a fibrinolytic matrix metalloproteinase is administered to a subject to degrade thrombus in situ. The fibrinolytic matrix metalloproteinase can be administered in conjunction with other active agents, preferably with agents having thrombolytic activity to improve thrombolytic and fibrinolytic therapy. The invention further provides compositions containing a fibrinolytic matrix metalloproteinase for the performance of fibrinolytic or thrombolytic procedures. Also provided are kits that include a fibrinolytic matrix metalloproteinase for performing fibrinolytic or thrombolytic procedures.
REFERENCES:
patent: 4610879 (1986-09-01), Markland, Jr. et al.
patent: 4813538 (1989-03-01), Blackman
patent: 5130143 (1992-07-01), Strickland et al.
patent: 5185001 (1993-02-01), Galanakis
patent: 5202121 (1993-04-01), Pohl et al.
patent: 5260059 (1993-11-01), Acott et al.
patent: 5260060 (1993-11-01), Markland et al.
patent: 5324634 (1994-06-01), Zucker
Francis CW, and Marder VJ, "Physiologic regulation and pathologic disorders of fibrinolysis", Chapter 54 in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd. ed., Colman RW, Hirsh J, Marder VJ, and Salzman EW, eds., JB Lippincott Co, Philadelphia (1994).
Collen D, "On the regulation and control of fibrinolysis", Thromb Haemost 43:77-89 (1980).
Collen D, and Lijnen HR, "Basic and clinical aspects of fibrinolysis and thrombolysis" Blood 3114-24 (1991).
Murphy G, Atkinson S, Ward R, Gavrilovic J, and Reynolds JJ, "The role of plasminogen activators in the regulation of connective tissue metalloproteinases", Ann NY Acad Sci, 667:1-12 (1992).
Singer et al., "VDIPEN, A Metalloproteinase-generated Neoepitope, Is Induced and Immunolocalized in Articular Cartilage during Inflammatory Arthritis", The Journal of Clinical Investigation, Inc., 95:2178-2186 (1995).
Martin GV, Kennedy JW, and Marder VJ, "Thrombolytic therapy for coronary artery disease", Chapter 73 in Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 3rd ed., Colman RW, Hirsh J, Marder VJ, and Salzman EW, eds., JB Lippincott Co, Philadelphia (1994).
Glick, BR and Pasternak JJ, "Molecular Biotechnology: Principles and Applications of Recombinant DNA", Chapter 17, pp. 403-420 (1994).
Collen D, "Biological properties of plasminogen activators", Chapter 1 in Sobel BE, Collen D, and Grossbard EB, eds., Tissue Plasminogen Activator in Thrombolytic Therapy, Marcel Dekker, Inc., New York (1987).
Lee SW, Kahn ML, and Dichek DA, "Control of clot lysis by gene transfer", Trends Cardiovasc Med 3:61-66 (1993).
Purves L, Purves M, and Brandt W, "Cleavage of fibrin-derived D-dimer into monomers by endopeptidase from puff adder venom (Bitis arietans) acting at cross-linked sites of the .gamma.-chain. Sequence of carboxy-terminal cyanogen bromide .gamma.-chain fragments", Biochemistry 26:4640-46 (1987).
Retzios AD, and Markland FS Jr, "Purification, characterization, and fibrinogen cleavage sites of three fibrinolytic enzymes from the venom of Crotalus basiliscus basiliscus", Biochemistry 31:4547-57 (1992).
Sanchez EF, Magalhes A, Mandelbaum FR, and Diniz CR, "Purification and characterization of the hemorrhagic Factor II from the venom of the Bushmaster snake (Lachesis muta muta)", Biochem Biophys Acta 1074:347-56 (1991).
Nagase H, Barrett AJ, and Woessner JF Jr, "Nomenclature and glossary of the matrix metalloproteinases", Matrix, Supplement No. 1:421-24 (1992).
Zavalova LL, Kuzina EV, Levina NB, and Baskova IP, "Monomerization of fragment DD by destabilase from the medicinal leech does not alter the N-terminal sequence of the .gamma.-chain", Thrombosis Res 71:241-44 (1993).
Budzynski AZ, "Interaction of hementin with fibrinogen and fibrin", Blood Coagulation and Fibrinolysis 2: 149-52 (1991).
Loewy AG, Santer UV, Wieczorek M, Blodgett JK, Jones SW, and Cheronis JC, "Purification and characterization of a novel zinc-proteinase from cultures of Aeromonas hydrophila", J Biol Chem 268:9071-78 (1993).
Cawston T, "Metalloproteinase inhibitors--Crystal gazing for a future therapy", Br J Rheumatol 30:242-44 (1991).
Kleiner DE Jr, and Stetler-Stevenson WG, "Structural biochemistry and activation of matrix metalloproteinase", Curr Opin Cell Biol 5:891-97 (1993).
Matrisian LM, "The matrix-degrading metalloproteinases", BioEssays 14:455-63 (1992).
Nagase H, Enghild JJ, Suzuki K, and Salvensen G, "Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteases and (4-aminophenyl)mercuric acetate", Biochemistry 29:5783-89 (1990).
Nagase H, Ogota Y, Suzuki K, Enghild JJ, and Salvensen G, "Substrate specificities and activation mechanisms of matrix metalloproteinases", Biochem Soc Trans 19:715-18 (1991).
Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, and Humphries S, "Localization of stromelysis gene expression in atherosclerotic plaques by in situ hybridization", Proc Natl Acad Sci USA 88:8154-58 (1991).
Galis ZS, Sukhova GK, Lark MW, and Libby P, "Increases expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques", J. Clin Invest 94:2493-2503 (1994).
Doolittle RF, "Fibrinogen and fibrin", in Bloom AL, and Thomas DP, eds., Hemostasis and Thrombosis Churchill Livingston, Edinburgh, New York (1987).
Fu Y, and Grieninger G, "Fib.sub.420 : A normal human variant of fibrinogen with two extended .alpha. chains", Proc Natl Acad Sci USA 91:2625-28 (1994).
Gabriel DA, Muga K, and Boothroyd EM, "The effect of fibrin structure on fibrinolysis", J Biol Chem 267:24259-63 (1992).
Kudryk BJ, Grossman ZD, McAffee JG, and Rosebrough SF, "Monoclonal antibodies as probes for fibrin(ogen)proteolysis", Chapter 19 in Monoclonal Antibodies in Immunoscintigraphy, Chatal J-F, ed., CRC Press, Boca Raton (1989).
Bini A, Mesa-Tejada RM, Fenoglio J, Kudryk B, and Kaplan KL, "Immunohistochemical Characterization of Fibrin(ogen)-Related Antigens in Human Tissues Using Monoclonal Antibodies", Laboratory Investigation, 60-814-821 (1989).
Bini A, Callender S, Pocyk R, Blomback B, and Kudryk BJ, "Flow and antibody binding properties of hydrated fibrins prepared from plasma, platelet rich plasma and whole blood", Thrombosis Res 76:145-56 (1994).
Okada Y, Nagase H, and Harris ED, Jr., "A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components", J Biol Chem 261:14245-55 (1986).
Tyagi SC, Ratajska A, and Weber LT, "Myocardial matrix metalloproteinase(s):localization and activation", Mol., Cell Biochem, 126:49-59 (1993).
Bini A and Kudryk BJ, "Fibrin and Its Derivatives in the Normal and Diseased Vessel Wall", in Plasminogen Activation in Fibrinolysis, in Tissue Remodeling and in Development, Ann NY Acad Sci, 677:112-126 (1992).
Bini A, Fenoglio J, Sobel J, Owen J, Fejgl M, and Kaplan KL, "Immunochemical Characterization of Fibrinogen, Fibrin I, and Fibrin II in Human Thrombi and Atherosclerotic Lesions", Blood, 69:1038-1045 (1987).
Bini A, Fenoglio J, Mesa-Tejada RM, Kudryk B, and Kaplan KL, "Identification and Distribution of Fibrinogen, Fibrin, and Fibrin(ogen) Degradation Products in Atherosclerosis, Use of Monoclonal Antibodies", Arteriosclerosis, 9:109-121 (1989).
Nagase H, "Matrix Metalloproteinases", Ch. 7 in Zinc Metalloproteases in Health and Disease, NM Hooper, ed., pp. 153-204 Taylor & Francis, London (1996).
Kemmerer Elizabeth
New York Blood, Inc.
LandOfFree
Inhibition of thrombus formation by medical related apparatus co does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of thrombus formation by medical related apparatus co, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of thrombus formation by medical related apparatus co will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-936665